S&P 500 Futures
(-0.03%) 5 306.50 points
Dow J Futures
(0.02%) 40 154 points
Nasdaq Futures
(-0.05%) 18 495 points
Oil
(0.60%) $81.84
Gas
(-0.81%) $1.704
Gold
(1.20%) $2 216.80
Silver
(-0.83%) $24.55
Platinum
(-0.38%) $906.25
USD/EUR
(0.36%) $0.927
USD/NOK
(0.68%) $10.84
USD/GBP
(0.25%) $0.793
USD/RUB
(-0.05%) $92.39

Realtime updates for Inovio Pharmaceuticals [INO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
80.00%
return 14.40%
SELL
66.67%
return -21.69%
Last Updated27 Mar 2024 @ 16:00

5.25% $ 13.03

BUY 61359 min ago

@ $7.33

Issued: 14 Feb 2024 @ 13:17


Return: 77.76%


Previous signal: Feb 14 - 09:30


Previous signal: Sell


Return: 6.23 %

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...

Stats
Today's Volume 291 785
Average Volume 540 669
Market Cap 304.52M
EPS $0 ( 2024-03-06 )
Next earnings date ( $-1.580 ) 2024-05-08
Last Dividend $0.0690 ( 2017-09-28 )
Next Dividend $0 ( N/A )
P/E -2.14
ATR14 $0.0320 (0.25%)
Insider Trading
Date Person Action Amount type
2024-02-26 Weiner David B. Buy 972 Common Stock
2024-02-26 Weiner David B. Buy 972 Common Stock
2024-02-26 Weiner David B. Buy 972 Common Stock
2024-02-26 Weiner David B. Sell 972 Restricted Stock Unit
2024-02-26 Weiner David B. Sell 972 Restricted Stock Unit
INSIDER POWER
61.29
Last 100 transactions
Buy: 3 683 868 | Sell: 932 723

Volume Correlation

Long: 0.03 (neutral)
Short: -0.28 (neutral)
Signal:(64.269) Neutral

Inovio Pharmaceuticals Correlation

10 Most Positive Correlations
AKTX0.966
LSXMA0.961
LSXMK0.961
STRO0.95
TUEM0.948
ASPU0.946
OPHC0.943
CMLS0.942
WATT0.942
AADI0.941
10 Most Negative Correlations
CPTA-0.952
SGEN-0.946
RAM-0.936
GPACU-0.936
NVSA-0.936
COCO-0.934
MLAI-0.932
PESI-0.928
PTOC-0.928
FRSG-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inovio Pharmaceuticals Correlation - Currency/Commodity

The country flag -0.40
( neutral )
The country flag -0.22
( neutral )
The country flag 0.00
( neutral )
The country flag -0.11
( neutral )
The country flag 0.69
( moderate )
The country flag -0.36
( neutral )

Inovio Pharmaceuticals Financials

Annual 2023
Revenue: $832 010
Gross Profit: $-2.67M (-321.09 %)
EPS: $-6.09
Q4 2023
Revenue: $102 651
Gross Profit: $-72 576.00 (-70.70 %)
EPS: $-1.100
Q3 2023
Revenue: $388 446
Gross Profit: $-644 329 (-165.87 %)
EPS: $-0.130
Q2 2023
Revenue: $225 971
Gross Profit: $-917 439 (-406.00 %)
EPS: $-0.130

Financial Reports:

No articles found.

Inovio Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Inovio Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 2.18 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $0.0690 2017-06-28
Last Dividend $0.0690 2017-09-28
Next Dividend $0 N/A
Payout Date 2017-10-16
Next Payout Date N/A
# dividends 4 --
Total Paid Out $0.276 --
Avg. Dividend % Per Year 0.00% --
Score 2.17 --
Div. Sustainability Score 2.18
Div.Growth Potential Score 0
Div. Directional Score 0.446 --
Next Divdend (Est)
(2024-06-24)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
2.17
Pay Frequency
Monthly
Yearly Payout
Year Amount Yield
2017 $0.276 3.90%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM3 430.551.50010.0010.00[0 - 0.5]
returnOnAssetsTTM16.501.20010.0010.00[0 - 0.3]
returnOnEquityTTM18.291.50010.0010.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.600.80010.008.00[1 - 3]
quickRatioTTM3.470.80010.008.00[0.8 - 2.5]
cashRatioTTM0.3361.5009.2410.00[0.2 - 2]
debtRatioTTM0.175-1.5007.09-10.00[0 - 0.6]
interestCoverageTTM-241.591.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-5.802.00-1.932-3.86[0 - 30]
freeCashFlowPerShareTTM-5.812.00-2.90-5.81[0 - 20]
debtEquityRatioTTM0.257-1.5008.97-10.00[0 - 2.5]
grossProfitMarginTTM-38.101.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-173.001.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-4.371.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.004810.800-3.30-2.64[0.5 - 2]
Total Score2.18

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM0.1041.000-0.09050[1 - 100]
returnOnEquityTTM18.292.5010.0010.00[0.1 - 1.5]
freeCashFlowPerShareTTM-5.812.00-1.936-5.81[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-5.802.00-1.932-3.86[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.006431.500-3.380[0.5 - 2]
operatingCashFlowSalesRatioTTM-158.771.000-10.000[0.1 - 0.5]
Total Score-1.289

Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators